Last update Aug. 23, 2021

C11 H17 N2 NaO3

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Barbiturate with hypnotic and sedative properties similar to amobarbital.
It has been used in insomnia and as a preanesthetic medication. Its use has been replaced by other drugs with less risk of abuse/dependence, overdose and withdrawal syndrome (Suddock 2020).
Oral or parenteral administration.

It is excreted in breast milk in a clinically insignificant amount (Horning 1975, cited in Wilson 1980).

Product with very few bibliographic and very old references in relation to breastfeeding. Commercialized in few countries.

Until more published data on this drug is available in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.


See below the information of this related product:

  • Amobarbital Sodium (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)

Alternatives

  • Clotiazepam (Safe product and/or breastfeeding is the best option.)
  • Dexmedetomidine Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Etomidate (Safe product and/or breastfeeding is the best option.)
  • Lorazepam (Safe product and/or breastfeeding is the best option.)
  • Methohexital (Safe product and/or breastfeeding is the best option.)
  • Zaleplon (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Zolpidem Tartrate (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C11 H17 N2 NaO3 is Pentobarbital Sodium in Molecular formula.

Is written in other languages:

C11 H17 N2 NaO3 is also known as

Groups

C11 H17 N2 NaO3 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing C11 H17 N2 NaO3 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 95 %
Molecular weight 248 daltons
Protein Binding 60 - 70 %
VD 0.65 l/Kg
pKa 7.9 -
Tmax 0.5 - 1 hours
26 (18 - 48) hours
Theoretical Dose 0.026 mg/Kg/d
Relative Dose 1.53 %

References

  1. Suddock JT, Cain MD. Barbiturate Toxicity. 2020 Jul 2. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Abstract
  2. Wilson JT, Brown RD, Cherek DR, Dailey JW, Hilman B, Jobe PC, Manno BR, Manno JE, Redetzki HM, Stewart JJ. Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet. 1980 Jan-Feb;5(1):1-66. Review. Abstract
  3. Breimer DD. Clinical pharmacokinetics of hypnotics. Clin Pharmacokinet. 1977 Mar-Apr;2(2):93-109. Review. No abstract available. Abstract
  4. Horning MG, Stillwell WG, Nowlin J, Lertratanangkoon, K, Stillwell RN, Hill RM. Identification and quantification of drugs and drug metabolites in human breast milk using GC-MS-COM methods. Modern Problems in Paediatrics 15: 73-79 (1975).

Total visits

1,133

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM